Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial

AI Briefing

• – Boehringer Ingelheim's survodutide achieves significant weight loss of 16.6% in Phase III trial, surpassing placebo by 13.4%.
• – Survodutide met co-primary endpoints for efficacy and treatment-regimen estimands in adults with obesity or overweight without type 2 diabetes.
• – Full data from the SYNCHRONIZE-1 trial to be presented at the American Diabetes Association's 2026 Scientific Sessions in June.